Relevant conflicts of interest/financial disclosures Nothing to declare. Full financial disclosures and author roles may be found in the online version of this article.
Pramipexole versus ropinirole: Polysomnographic acute effects in restless legs syndrome†
Article first published online: 2 MAR 2011
Copyright © 2011 Movement Disorder Society
Volume 26, Issue 5, pages 892–895, April 2011
How to Cite
Manconi, M., Ferri, R., Zucconi, M., Oldani, A., Giarolli, L., Bottasini, V. and Ferini-Strambi, L. (2011), Pramipexole versus ropinirole: Polysomnographic acute effects in restless legs syndrome. Mov. Disord., 26: 892–895. doi: 10.1002/mds.23543
- Issue published online: 21 APR 2011
- Article first published online: 2 MAR 2011
- Manuscript Accepted: 18 OCT 2010
- Manuscript Revised: 7 OCT 2010
- Manuscript Received: 28 JUN 2010
- restless legs syndrome;
- periodic leg movements;
Background: Pramipexole and ropinirole have become the first-line treatment for restless legs syndrome. The aim of this study was to perform the first direct comparison between these two molecules in restless legs syndrome. Methods: A double-blind, placebo-controlled, double-night and prospective investigation was carried out in 45 consecutive naïve patients with idiopathic restless legs syndrome. Each patient underwent two consecutive full-night polysomnographies: the first baseline recording was performed without premedication and, before the second recording, first group received a single oral dose of 0.25 mg pramipexole, second group a single oral dose of 0.5 mg ropinirole, and the remaining patients received placebo.
Results and Discussion: Both dopamine agonists improved restless legs syndrome symptoms and markedly suppressed periodic leg movements during sleep compared to placebo, without significant differences between pramipexole and ropinirole. No significant side effects, except for mild morning nausea (2 patients treated with ropinirole, 3 with pramipexole, and 1 with placebo), were reported. © 2011 Movement Disorder Society